Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | HTR7 | P34969 | 5/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24324306 | 0.93 | KCNH2 (0.59) | KCNH2SLC6A2SLC6A4CYP2D6DRD2 | |
| SCHEMBL4775703 | 0.81 | CCR3 (0.59) | KCNH2SLC6A2SLC6A4SIGMAR1 | |
| SCHEMBL24322696 | 0.80 | DRD2 (0.56) | CYP2D6DRD2HTR7DRD4DRD3 | |
| SCHEMBL7949267 | 0.78 | SIGMAR1 (0.49) | CYP2D6SIGMAR1 | |
| SCHEMBL22856216 | 0.78 | SIGMAR1 (0.49) | CYP2D6SIGMAR1 | |
| SCHEMBL8031282 | 0.77 | GNAI3 (0.46) | SIGMAR1 | |
| SCHEMBL7375511 | 0.76 | SIGMAR1 (0.65) | KCNH2SLC6A2SLC6A4CYP2D6DRD2 | |
| SCHEMBL13532848 | 0.76 | HTR7 (0.69) | KCNH2DRD2HTR7DRD4DRD3 | |
| SCHEMBL8041290 | 0.76 | ALDH1A1 (0.58) | CYP2D6 | |
| SCHEMBL22848104 | 0.75 | DRD2 (0.58) | KCNH2DRD2DRD4DRD3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | KCNH2 4773/4885SLC6A2 2464/4885SLC6A4 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.